MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 466140 | Name: BRL42715

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BRL42715 is an active-site-directed inactivator of bacterial beta-lactamases.

Chemical Structure

BRL42715
BRL42715
CAS#102209-75-6 (sodium)

Theoretical Analysis

MedKoo Cat#: 466140

Name: BRL42715

CAS#: 102209-75-6 (sodium)

Chemical Formula: C10H7N4NaO3S

Exact Mass: 286.0137

Molecular Weight: 286.24

Elemental Analysis: C, 41.96; H, 2.47; N, 19.57; Na, 8.03; O, 16.77; S, 11.20

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BRL42715; BRL 42715; BRL-42715;
IUPAC/Chemical Name
sodium (R,E)-6-((1-methyl-1H-1,2,3-triazol-4-yl)methylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
InChi Key
OMJBLZMKGVWHQP-MPXWGJQKSA-M
InChi Code
InChI=1S/C10H8N4O3S.Na/c1-13-3-5(11-12-13)2-6-8(15)14-7(10(16)17)4-18-9(6)14;/h2-4,9H,1H3,(H,16,17);/q;+1/p-1/b6-2+;/t9-;/m1./s1
SMILES Code
O=C(C(N1C/2=O)=CS[C@]1([H])C2=C\C3=CN(C)N=N3)[O-].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 286.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jones RN, Deshpande LM, Bell JM, Turnidge JD, Kohno S, Hirakata Y, Ono Y, Miyazawa Y, Kawakama S, Inoue M, Hirata Y, Toleman MA. Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002). Diagn Microbiol Infect Dis. 2004 Aug;49(4):289-94. doi: 10.1016/j.diagmicrobio.2004.04.007. PMID: 15313535. 2: Yamaguchi K, Mathai D, Biedenbach DJ, Lewis MT, Gales AC, Jones RN. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis. 1999 Jun;34(2):123-34. doi: 10.1016/s0732-8893(99)00019-x. PMID: 10354863. 3: Li XZ, Zhang L, Srikumar R, Poole K. Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998 Feb;42(2):399-403. doi: 10.1128/AAC.42.2.399. PMID: 9527793; PMCID: PMC105421. 4: Phillips OA, Czajkowski DP, Spevak P, Singh MP, Hanehara-Kunugita C, Hyodo A, Micetich RG, Maiti SN. SYN-1012: a new beta-lactamase inhibitor of penem skeleton. J Antibiot (Tokyo). 1997 Apr;50(4):350-6. doi: 10.7164/antibiotics.50.350. PMID: 9186563. 5: Kunugita C, Higashitani F, Hyodo A, Unemi N, Inoue M. Characterization of a new plasmid-mediated extended-spectrum beta-lactamase from Serratia marcescens. J Antibiot (Tokyo). 1995 Dec;48(12):1453-9. doi: 10.7164/antibiotics.48.1453. PMID: 8557603. 6: Satake S, Nakae T. Outer membrane permeability of beta-lactamase inhibitors in Pseudomonas aeruginosa. FEMS Microbiol Lett. 1995 Jun 15;129(2-3):251-4. doi: 10.1111/j.1574-6968.1995.tb07588.x. PMID: 7607408. 7: Galleni M, Franceschini N, Quinting B, Fattorini L, Orefici G, Oratore A, Frère JM, Amicosante G. Use of the chromosomal class A beta-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory beta-lactam compounds. Antimicrob Agents Chemother. 1994 Jul;38(7):1608-14. doi: 10.1128/AAC.38.7.1608. PMID: 7979294; PMCID: PMC284600. 8: Muratani T, Yokota E, Nakane T, Inoue E, Mitsuhashi S. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam. J Antimicrob Chemother. 1993 Sep;32(3):421-9. doi: 10.1093/jac/32.3.421. PMID: 8262864. 9: Zhou XY, Kitzis MD, Gutmann L. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1993 Jun;37(6):1387-9. doi: 10.1128/AAC.37.6.1387. PMID: 8328794; PMCID: PMC187975. 10: Ephtimios IE, Barrett MS, Wenzel RP, Jones RN. In-vitro antimicrobial activity of the penem BRL-42715, alone and in combination with ampicillin, against respiratory tract pathogens. J Antimicrob Chemother. 1992 May;29(5):599-600. doi: 10.1093/jac/29.5.599. PMID: 1624400. 11: Livermore DM, Seetulsingh P. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin . J Antimicrob Chemother. 1991 Jun;27(6):761-7. doi: 10.1093/jac/27.6.761. PMID: 1669013. 12: Jackson D. Evolution of beta-lactamase inhibitors. Pharmacotherapy. 1991;11(2 ( Pt 2)):37S-39S. PMID: 2041830.